LBI-HTA - Publications - Search - Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer

Nachtnebel, A. (2010): Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 09.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
183Kb
Abstract

First-line therapy with lapatinib in the advanced/metastatic breast cancer setting was assessed in two phase III trials. Progression-free survival was improved by about 5 months in HER2 and hormone receptor positive women but similar data for gains in overall survival are still missing. Hence, it seems that the primary benefit of orally administered lapatinib is the potential of delaying more aggressive therapies with considerable toxicities in a well-defined hormone receptor/HER2 positive population.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:cancer, lapatinib, tyrosine kinase inhibitor, oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
WP Gynaecology > WP 800-910 Breast
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:DSD: Horizon Scanning in Oncology 09
Deposited on:14 Jul 2010 12:38
Last Modified:14 Jul 2010 12:38

Repository Staff Only: item control page